MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text

Life Sciences, Immunology, Oncology +17

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Michael S. Lawrence, Petar Stojanov, Paz Polak et al. · Nature · 2013 · 5.7K citations · Full text

Medicine, Genetics, Oncology +14

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz et al. · Nature · 2014 · 5.3K citations

Medicine, Immunology, Oncology +16

Mutational landscape and significance across 12 major cancer types

Cyriac Kandoth, Michael D. McLellan, Fabio Vandin et al. · Nature · 2013 · 4.5K citations · Full text

Medicine, Genetics, Oncology +17